an Approach to Dyspepsia
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

an Approach to Dyspepsia

  • 3,702 views
Uploaded on

quoted from NICE, Dyspepsia

quoted from NICE, Dyspepsia

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
3,702
On Slideshare
3,702
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
166
Comments
0
Likes
2

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • Epigastric pain – most common Burning pain Aggrav by eating Alleviated by antacids belching/bloating
  • Prior hx PUD Ibuprofen Tobacco ETOH Caffeine Poss stress
  • Dys=
  • The following are some theories as to possible causes:Sensation in the stomach or duodenum may be altered in some way - an 'irritable stomach'. About 1 in 3 people with non-ulcer dyspepsia also have 'irritable bowel syndrome' and have additional symptoms of lower abdominal pains, erratic bowel movements, etc. The cause of irritable bowel syndrome is not known.A delay in emptying the stomach contents into the duodenum may be a factor in some cases. The muscles in the stomach wall may not work as well as they should.Infection with a bacterium (germ) called H. pylori may cause some cases. This bacterium is found in the stomach in some people with non-ulcer dyspepsia. However, many people are 'carriers' of this bacterium, and it causes no symptoms in most people. The role of H. pylori is controversial in non-ulcer dyspepsia (although it is the main cause of duodenal and stomach ulcers). However, getting rid of H. pylori infection helps in some cases.Some people feel that certain foods and drinks may cause the symptoms or make them worse. It is difficult to prove this. Foods and drinks that have been suspected of causing symptoms or making symptoms worse in some people include: peppermint, tomatoes, chocolate, spicy foods, hot drinks, coffee, and alcoholic drinks. However, food is not thought to be a major factor in most cases.Anxiety, depression, or stress are thought to make symptoms worse in some cases.A side-effect of some drugs can cause dyspepsia. The most common culprits are anti-inflammatory drugs such as ibuprofen and aspirin. Various other drugs which sometimes cause dyspepsia, or make dyspepsia worse, include: antibiotics, steroids, iron, calcium antagonists, nitrates, theophyllines, bisphosphonates. (Note: this is not an exhaustive list. Check with the leaflet that comes with your medication for a list of possible side-effects.) If you suspect a prescribed drug is causing the symptoms, or making them worse, then see your doctor to discuss possible alternatives.
  • Non-ulcer dyspepsia (NUD), sometimes called ‘functional’ dyspepsia, refers to patients whose endoscopic investigation has excluded gastric or duodenal ulcer, malignancy or oesophagitis. Simple gastritis or duodenitis found by endoscopy are not considered significant abnormalities, but erosive duodenitis and gastric erosions are considered part of the spectrum of ulcer disease. The Rome II definition [4] further excludes patients with predominant heartburn and without oesophagitis as ‘endoscopy negative reflux disease’ (ENRD) and those with pain relieved by defecation as irritable bowel syndrome.   Non-ulcer dyspepsia (including ENRD) accounts for the majority of dyspeptic patients at endoscopy. Trials indicate that, untreated, at least 70% of these patients will have persistent symptoms a year after diagnosis: unlike peptic ulcer disease there is no ‘one off’ cure and treatment may often be needed on a long-term basis. A Swedish study followed 1,059 individuals for a year and found that only 12% of those originally with dyspeptic symptoms were asymptomatic and 16% were classed as having irritable bowel syndrome, one year later [390].   There is uncertainty about the definition and cause of non-ulcer dyspepsia. The long term value of available symptomatic treatments rests upon extrapolation from short term trials. There is considerable uncertainty about the appropriate long term management of patients with persistent symptoms. In the light of this uncertainty, patients should be offered periodic review of their condition and medication, with a trial of reduced use if appropriate.   Previously published reviews of H. pylori and pharmacological therapies have been updated to evaluate specific treatments for NUD include antacids, H2RAs, PPIs, prokinetic agents, H. pylori eradication and psychological interventions.   Available evidence from trials indicates that eradication of H. pylori (if present) is an effective and cost-ffective option. Benefit is obtained by a short course of therapy, whilst acid suppression requires long term treatment. Thus eradication therapy is more likely to be cost-effective in spite of its small treatment effect on symptoms. Long term acid suppression is appropriate for H. pylori negative patients and those failing to respond to eradication. Short term evidence from trials shows that both PPIs and H2RAs can reduce the symptoms of dyspepsia, but there are methodological concerns about the interpretation of these trials. On balance PPIs are recommended over H2RAs on pharmacological grounds and the quality of available trials, while the cost of maintenance dose PPIs and H2RAs is similar.   It is possible that different therapies are working selectively on particular kinds of patient, in which case available treatments should not be regarded as mutually exclusive options
  •   There are a variety of non-invasive tests for H. pylori [397]. Serology has been widely used in clinical practice and two meta-analyses [398,399] indicate that sensitivity and specificity are usually greater than 85% (Table 19). Laboratory-based testing is relatively inexpensive (at a total cost of about £10) and medication does not interfere with the accuracy of the test [400]. The sensitivity and specificity of serology varies in different populations. The reason for this is uncertain but may relate to different strains of H. pylori or genetic differences in the population causing diverse immune responses. The appropriate cut-off for a commercial kit being used should therefore be locally validated [401].     Near patient serology tests have been developed, where the result is obtained in situ rather than from a laboratory [402], but the accuracy of these kits varies widely in different communities [403]. Detecting antibodies to H. pylori antigens in the saliva is another non-invasive method of diagnosing the infection, but again the accuracy of this method is inconsistent across different populations [404].     Urea breath tests are consistently accurate with about 95% sensitivity and specificity reported in studies but have reduced accuracy in patients taking antibiotics or PPIs [405]. 14 C-urea breath tests are not appropriate for primary care as they involve a small dose of radiation. 13 C-urea breath tests do not involve ionising radiation and are simple to perform although they are relatively expensive at about £19 per test. Faecal antigen tests appear to perform as well as urea breath tests may be cheaper at about £11 per test, although patient acceptability with this form of testing may be a problem [406].   The Health Protection Agency Helicobacter Working Group does not recommend the routine use of serology because of the poor positive predictive value in populations with low prevalence [407]. Serology fails to diagnose patients with active disease, it merely indicates if an individual has ever encountered the antigen. This means that significant numbers of patients will be falsely diagnosed as positive and thus be inappropriately treated, possibly have their true diagnosis missed or delayed. They also note that all serological kits are unhelpful in children and less reliable in older patients. Realistically it is very difficult to undertake local validation of kits and laboratories tend to accept commercial companies’ assurances of kits. The guideline group did not consider that serology performs adequately when compared to the laboratory based stool antigen tests and Urea Breath Tests that are now available.              
  • 1 If NSAID continuation is necessary, after ulcer healing offer long term gastric protection or consider substitution to a newer COX-selective NSAID. 2 Use a carbon-13 urea breath test, stool antigen test or, when performance has been validated, laboratory-based serology. 3 Use a PPI, amoxicillin, clarithromycin 500 mg (PAC 500 ) regimen or a PPI, metronidazole, clarithromycin 250 mg (PMC 250 ) regimen. Follow guidance found in the British National Formulary for selecting 2 nd line therapies. After two attempts at eradication manage as H. pylori negative. 4 Perform endoscopy 6-8 weeks after treatment. If retesting for H. pylori use a carbon-13 urea breath test. 5 Offer low dose treatment, possibly used on an as required basis, with a limited number of repeat prescriptions. 6 Review care annually to discuss symptoms, promote stepwise withdrawal of therapy when appropriate and provide lifestyle advice. In some patients with an inadequate response to therapy it may become appropriate to refer to a specialist. ------------- If NSAID continuation is necessary, after ulcer healing offer long term gastric protection or consider substitution to a newer COX-selective NSAID. Use a carbon-13 urea breath test, stool antigen test or, when performance has been validated, laboratory-based serology. Use a PPI, amoxicillin, clarithromycin 500 mg (PAC 500 ) regimen or a PPI, metronidazole, clarithromycin 250 mg (PMC 250 ) regimen. Use a carbon-13 urea breath test. Follow guidance found in the British National Formulary for selecting 2 nd line therapies. Offer low dose treatment, possibly on an as required basis, with a limited number of repeat prescriptions. Consider: non-compliance with treatment, possible malignancy, failure to detect H. pylori infection due to recent PPI or antibiotic ingestion, inadequate testing, or simple misclassification; surreptitious or inadvertent NSAID or aspirin use; ulceration due to ingestion of other drugs; Zollinger-Ellison syndrome; Crohn’s disease. A small number of patients with chronic, refractory peptic ulceration may require maintenance acid suppression. In some patients with an inadequate response to therapy it may become appropriate to refer to a specialist for a second opinion.
  • Dyspepsia with acute Upper GI bleeding?

Transcript

  • 1. An approach to Dyspepsia Al-Momtan, Ahmed Tahir C-2
  • 2. Case Presentation
  • 3. P/P and HPI
    • Mr. Al-Momtan, Tahir Abdullah is a 56 year old male who presented to our clinic with epigastric abdominal pain x 2 weeks. He describes it as a burning pain which is non-radiating and is worse after he eats. He has frequent belching with bloating sensation but denies nausea, vomiting, diarrhea, constipation, or weight loss. He has tried epicogel ® found to be composed of ( Each 5 ml contains Dried aluminium hydroxide gel 405 mg, Magnesium hydroxide 100 mg, Dimethicone 125 mg) in which he claimed, “helps a little”.
  • 4. Mr Al-Momtan History
    • PMH: HTN stable diagnosed 4 years ago, Osteoarthritis in knees, treated for an ulcer 3 years ago
    • Meds: Hydrochlorothiazide 25 mg twice daily, ibuprofen 400 mg X 4 times daily
    • Soc HX: Married, worked in his local municipal a civil engineer and now a Manager of a private business, drinks 2-4 cups coffee per day, no Hx of alcohol intake or smoking.
  • 5. Mr. Al-Momtan Physical Exam
    • VS: BP 137/82, HR 85, afeb, RR 14
    • HEENT: conjunctiva pink, clear OP MMM
    • Heart: RRR no M/R/G
    • ABD: Soft, NABS, mild-moderate epigastric TTP, no HSM or masses, no acute abd signs
    • Skin: no pallor
    • Rectal: stool brown, heme (-), no masses
  • 6. Mr. Tahir Prior Ulcer History
    • On further questioning Mr. Al-Momtan states he had similar abdominal pain three years ago and was told by his physician at that time that it was most likely due to an “ulcer”. He took “the purple pill” for a month and his symptoms resolved. He had no definitive diagnostic tests done at that time.
  • 7. Diagnosed
    • From his clinical Hx and PE plus
    • CBC, Urea breath test were done for him, the patient was diagnosed to have a PUD.
    • Given an appointment for Upper GI endoscopy but he refused.
  • 8. Treatment
    • Sent home, Started on Tripple therapy composed of 2 antibiotics and a PPI:
      • Clarythromycine 500 mg PO bid for 2 weeks
      • Metronidazole 500 mg PO bid for 2 weeks
      • Lansoprazole 30 mg PO bid for 3 weeks
      • Asked to visit the clinic 4 weeks later..
  • 9. Objectives
    • To review some common causes
    • • To review the evidence based management strategies
    • • What to treat & when to to refer safely & effectively ??
  • 10. Definition
    • Group of symptoms consisting mostly upper abdominal or epigastric pain or discomfort, heartburn, or acid regurgitation.Often associated with belching, bloating, nausea or vomiting
  • 11. INTRODUCTION • Dyspepsia • 40% of adult population / year, 2% consult their GPs • Substantial health care cost: - - - Medication Diagnostic evaluation Time cost from work • Out of 100 pts. 90% will be pain free after 2-3 wks without Rx • Definitive established guideline (NICE) • H.pylori & PUD – well accepted & confirmed
  • 12. 5 common causes of dyspepsia 1- NUD. 2- GORD 3- Gastritis 4- Gastric Ulcer. 5- Doudenal Ulcer Rare causes Gastic and oesophageal CA.
  • 13. Less common causes of upper abdominal pain
    • Aerophagy.
    • Biliary colic
    • Abdominal wall pain
    • Malignancy
    • Mesenteric vascular insuffeciency
    • Angina
    • Metabolic disease
  • 14. Drugs associated with dyspepsia
    • NSAIDs
    • Iron.
    • Metformin
    • Codiene
    • Antibiotics
    • Orlistat
    • Corticosteroids
    • theophyllin
    • Digoxin.
    • Colchicine
    • Alendronate.
    • Nitrates
    • Quinidine
    • Gemfibrozil
    • ,,,,
  • 15. 5 common Diagnoses
    • 1- NUD (non-ulcer dyspepsia)
      • most common cause.
      • Younger age group more than later life.
      • Causes?
      • GI motility?
      • Gastric secretion  normal
      • Presence of H-pylori.
      • Incidence decrease with advancing age.
  • 16. Pathophysiology
    • Functional dyspepsia
  • 17. T/T of functional dyspepsia
    • Initial treatment
      • • Diet , beverages, smoking
      • • Antisecretory drug (H2RAs, PPI)
      • or
      • • Prokinetic drug (domperidone) if antisecretory treatment fails
      • • Switch treatment if first drug type fails
    • Stats,,
    • • Systematic review (98 randomised controlled trials) The Cochrane Library, Issue 1, 2005. :
    • • RRR = 48% in the Prokinetics group compared to placebo.
    • • RRR = 22%; in the H2RAs group
    • • RRR = 14%; in PPI group
    • • Antacid & bismuth effects were not statically significant
  • 18. NICE flowchart (functional dyspepsia)
  • 19. Cont. T/T of functional dyspepsia
      • Resistant cases (failed initial treatment) :
        • • H.pylori eradication
        • • Sucralfate or bismuth
        • • Antispasmodic agent( such as mebeverine)
        • • Antidepressant (such as SSRI or tricyclic drug)
        • • Behavioural therapy or psychotherapy
        • • No treatment is proved tobe fully beneficial in these patients.
    • stats:
      • • Systematic review (17 randomised controlled trials) The Cochrane Library, Issue 1, 2005. :
      • • RRR= 8% in the H pylori eradication group (95% CI = 3% to 12%) compared to placebo. NNT to cure one case of dyspepsia = 18
  • 20. 5 common Diagnoses
    • 2- GORD (Gastroesophageal reflux disease)
      • • Very common
      • • Heartburn , Sharp stabbing sub-sternal pain (probability :89%)
      • • Regurgitation (probability :95%)
      • • At night or after heavy meal
      • • Chronic cough, asthma like wheezing
      • • MI ??
  • 21. GORD, Cont.
  • 22. GORD, Cont.
    • Weakness or incompetence of lower esophageal sphincter
    • Esophagitis, esophageal structure
    • Barret’s esophagus
    • • Dx:
      • Hx,PPI test, 24 hours pH manometer!,,Endoscopy??
    • Lifestyle modification??
    • • Medication:
      • Antacid
      • Antisecretory drug: H2 receptor blocker
      • proton pump inhibitor (2months)
    • • Prokinetics
    • Surgery: Laproscopic fundoplication or open?
    Dx and Management
  • 23. 5 common Diagnoses
    • 3- PUD (Peptic ulcer disease)
      • • Less than before
      • • P/H ulcer, recurrence more likely
      • • Risk factors include:
        • -H-pylori
        • -Family Hx
        • -NSAID -Cigarette smoking
        • -Chronic renal failure
        • -Blood group “O”
  • 24. complications
    • Weakness or incompetence of lower esophageal sphincter
    • Esophagitis, esophageal structure
    • Barret’s esophagus
    Diagnostic Difficulties
    • Not text book presentation
    • Early presentation
    • History:
    • 1.ALARM symptoms ??
    • 2.Specific symptoms
    • 3.NUD
      • MI ??
      • NSAID
      • Smoking
  • 25. ALARM Symptoms! ALARM! • A norexia • L oss of weight (progressive & unintentional) • A naemia due to iron deficiency • R ecent onset of persistent symptoms :vomiting • M elaena, haematemesis • Dysphagia (progressive) • Epigastric mass or • Suspicious barium meal.
  • 26. General Management
    • 1.Management of symptoms in primary care is appropriate for most patients rather than routinely seeking a pathological diagnosis.
    • 2.Alarm signals and signs are the major determinant of the need for endoscopy, not age on its own.
    • 3.Long term care should emphasize patient empowerment with ‘on demand’ use of the lowest effective dose PPI.
  • 27. Cont. General Management
    • • Simple lifestyle advice: healthy eating, weight reduction, smoking cessation
    • • Offer empirical antacid,H2Aor PPI therapy for one month to patients with dyspepsia.
  • 28. H. Pylori
    • Gram–ve, flagellated spiral
    • Casually related to:
      • GU
      • DU
      • Gastritis
      • Gastric B – cell lymphoma
      • Gastric adenoma
    • Prevalence-high
    • More in developing countries
    • Roughly related to age
    • • Saudi local study 67-89%
  • 29. H. Pylori Testing and Eradication
    • • Serology
    • • Urea Breath test
    • • Fecal antigen test
    • • Endoscopy
    • • Stript test
    • Benefits:
      • Cure rate.
      • Recurrence
      • Bleeding
    • **All cases of dyspepsia ??
    H-PYLORI ERADICATION - Triple regimen: Proton pump inhibitor + two antibiotics
  • 30. Flowcharts, DU and GU
  • 31. Endoscopy • Age < 55 years, presenting with dyspepsia and without alarm S/S, is not necessary. • Age > 55 years presenting with dyspepsia and without alarm S/S do not require routine endoscopy. Considered if : 1.ALARM signals and signs are the major determinant of the need for endoscopy, not age on its own. 2. No response to medication7-10days. 3. Symptoms persist after 6-8wks 4. Signs of systemic illness 5. Recurrence after treatment 6. Long standing G0RD 7. Unexplained weight loss, progressive dysphagia, IDA, abdominal mass on plapation
  • 32. Cont. Endoscopy
    • Patients undergoing endoscopy should be free from medication with either a PPI or an H2 receptor antagonist for a minimum of two weeks.
  • 33. Reasons for referral
    • immediate?
    • If highly suggestive of cardiac or biliary disesases
    • • cancer suspected or proven;
    • • diagnostic uncertainty;
    • • treatments not available
    • • failure of treatment, symptoms persisting;
    • • patients' wishes
  • 34. Referral flowchart
  • 35. Take home message!!
    • Aggravating factors :tobacco, ASA, NSAIDs,other medications and alcohol
    • Alarm features –absent OR present.
    • A. Alarm features – abscent:
        • Two approaches are acceptable:
    • 1. Test for H. pylori infection
    • 2. Empiric Therapy
    • – A4-week course a histamine-2 receptor – antagonist or PPI
    • **Failure to respond to treatment justifies further investigation and/or referral
    • B. Alarm features – present:
        • Endoscopy ± biopsy,
        • referral Barium may be as an alternative..
        • Life style modification ??